P3-176: Prognostic factors for patients with advanced and metastatic non small cell lung cancer (NSCLC): classical factors= performans status (PS), gender and extension of disease; new factors= expression of EGFR, p53 and cell proliferation defined by Ki67

Abstract

The aim of the study was to assess the relation between new factors prognostic (expression of EGFR, p53, cell proliferation defined by the monoclonal antibody Ki67); classical factors prognostic (performans status PS, age, gender, extension of the disease) and survival of patients with non-small cell lung cancer stage III and IV. Patient and Methods: 80 patients were included in this study (male 72 / female 8); the median follow up was 15 months. All tumor samples were formalin-fixed and paraffin-embedded. The expression of p53, EGFR and Ki 67 were assessed with the use of im-munohistochemically (IHC). P53 was assessed in 66 cases, EGFR in 73 cases and cell proliferation defined by the monoclonal antibody Ki67 in 63 cases. The expression of p53 was positive in 20 % of cases, EGFR was positive in 58,7 % of cases and cell proliferation in 40 % of cases. Survival was estimated from the date of first cycle of chemotherapy using median survival and the Kaplan-Meier survival analysis method. for each factor. Tabled 1Median survival (month)pp53 positive5,030,2p53 negative8,2Ki67 positive5,30,5Ki67 negative8,4EGFR positive5,30,5EGFR negative8,2Median survival (months)PPS = 011,810-6PS =14,1PS = 21,6Age less 59 years5,40,9Age > 59 years8,2Female7,50,5Male5N09,70,008N11,3N28,3N35,2 Open table in a new tab At this time of the study, there was no relation between expression of p53, EGFR, cell proliferation defined by ki67 and survival. Correlation between PS, nodes extension and survival is confirmed. Larger and longer follow-up studies may be needed to determine the prognostic role of expression of those new factors in NSCLC.